Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › DMARDs

DMARDs

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of DMARDs

6 trials tracked of DMARDs: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 55 citations.

6Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 3
  1. Phase 4 RHYTHM (Formerly Escape II Myocardium) Completed · 55 cited
  2. Phase 3 A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent Completed · 38 cited
  3. Phase 3 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed · 38 cited
  4. Phase 4 A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 Completed
  5. Phase 4 Rheumatoid Arthritis Memory B Cells and Abatacept Completed
  6. Phase 3 A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
JAK inhibitors maintain efficacy in patients with multiple prior biologic DMARD failures
Rheumatology Meta-analysis
JAK inhibitors maintain efficacy in patients with multiple prior biologic DMARD failures New Options Found for Difficult to Treat Rheumatoid Arthritis
This meta-analysis of 131 studies evaluates treatments for difficult-to-treat rheumatoid arthritis (D2T RA). The analysis found that Janus k…
Patients with difficult to treat rheumatoid arthritis may have more effective options when previous medications fail to control their sympto…
Aug 5, 2026
Evaluating Treat to Target Outcomes in Elderly and Young Rheumatoid Arthritis Patients
Rheumatology RCT
Evaluating Treat to Target Outcomes in Elderly and Young Rheumatoid Arthritis Patients Treat-to-Target Strategy Shows Promise for Elderly Rheumatoid Arthritis
A multicenter trial confirms that elderly patients achieve similar clinical outcomes and safety profiles as younger cohorts under a standard…
A new study shows that elderly patients with rheumatoid arthritis can achieve similar results to younger patients using a standard treat-to-…
Jul 4, 2026
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis
Rheumatology Meta-analysis
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients
This meta-analysis reviewed data from over 5000 patients with late-onset rheumatoid arthritis (LORA) and young-onset rheumatoid arthritis (Y…
A large review found older patients with rheumatoid arthritis had higher disease activity and lower remission rates on biologics compared to…
May 1, 2026